Take our post-test to claim CME credits.To listen to our full-length podcast, click here. Hosted on Acast. See acast.com/privacy for more information.

Take our post-test to claim CME credits.To listen to our full-length podcast, click here. Hosted on Acast. See acast.com/privacy for more information.

Take our post-test to claim CME credits.To listen to our full-length podcast, click here. Hosted on Acast. See acast.com/privacy for more information.

Hepatitis B. It may not be curable yet, but as our knowledge continues to grow, so does our ability to benefit our patients today as we prepare them for tomorrow. Thats the focus of this Special HBV Edition of eViralHepatitis Review.The first part o

The challenges researchers currently face in developing new hepatitis B treatments.

The best practices for treating HCV among PWID and the impact of injection drug use on adherence, on cure rates, and on the risk of reinfection after successful HCV therapy.

The significant morbidity and mortality that may be caused by hepatitis C-related extrahepatic manifestations. How hepatitis C treatment can favorably impact the course of extrahepatic manifestations.

The challenges of the timing of treatment for HCV patients with decompensated cirrhosis who are on the wait list for liver transplantation.

The factors that may contribute to patient attitudes about HBV testing and care. Potential barriers and solutions to improve HBV care in the peri-partum setting.

The outcomes of HCV treatment with direct-acting antivirals (DAAs) in persons with recent injection drug use. Barriers to the treatment of HCV for people who inject drugs.